The Part A/B Open Public Meetings are scheduled by the Noridian Contractor Medical Director(s) of Noridian Healthcare Solutions - A/B Medicare Administrative Contractor (MAC). The MolDX open public meeting is to allow the public to submit information for Noridian's consideration in Medicare MolDX Local Coverage Determination (LCD) development; however, specific claims are not discussed during these meetings.
Attendance
Participate in one of two ways.
Registration is required.
- Attend in-person
- To register, select "Register Now" below no later than one week prior to event. Space is limited. Please limit in-person participation requests to only those who will actively participate and contribute to the discussions
- Attend via teleconference
- To register, select "Register Now" link below
- Upon registration a telephone number, access code, and audio PIN will be provided to you. Do not share this information
Presenters / Speakers
- If you plan to make a presentation at this meeting, you must designate at registration or you will not be allowed to do so. Time to present will be determined by the number of presenters. Only one presentation from each entity.
- All final presentations must be submitted to OpenMeeting@noridian.com by the date below. Indicate in your email which MolDX LCD you will be presenting on.
State |
Date |
Time |
In Person Location |
Teleconference |
Agenda Topics |
Presentations Due |
All |
10/10/24 |
1 - 3 p.m. CT |
Teleconference Only |
|
|
10/03/24 |
Previous Meeting Documents and Recordings
State |
Date |
Agenda Topics |
Recordings |
All |
09/13/24 |
- MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms
- Agenda
|
Recording and Transcript |
All |
10/11/23 |
- MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
- MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
- MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
- Agenda [PDF]
|
Recording and Transcript |
All |
09/20/23 |
- MolDX: Molecular Testing for Solid Organ Allograft Rejection
- Agenda [PDF]
|
Recording and Transcript |
All |
07/18/23 |
- MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
- Agenda [PDF]
|
Recording and Transcript |
All |
10/20/22 |
- MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
- Agenda [PDF]
|
Recording and Transcript |
All |
08/11/22 |
- MolDx: Molecular Assays for the Diagnosis of Cutaneous Melanoma
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
- Agenda [PDF]
|
Recording and Transcript |
All |
05/26/22 |
- Lumbar Epidural Injections
- MolDX: 4 KScore® Assay
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia
- Nerve Blockade for Treatment of Chronic Pain and Neuropathy
- Agenda [PDF]
|
Recording and Transcript |
All |
2/24/22 |
- LCD: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease
- LCD: MolDX: Plasma-Based Genomic Profiling in Solid Tumors
- LCD: Epidural Steroid Injections for Pain Management
- Agenda [PDF]
|
Recording and Transcript |
All |
06/24/21 |
- MolDX: Melanoma Risk Stratification Molecular Testing
- MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
- MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
- MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
- Agenda [PDF]
|
Recording and Transcript |
All |
10/28/20 |
- MolDX: Minimal Residual Disease Testing for Cancer
- Agenda [PDF]
|
Recording and Transcript |
All |
06/04/20 |
- MolDX: Liquid Biopsies for Solid Organ Transplantation
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
- Agenda [PDF]
|
Recording and Transcript |
All |
06/03/20 |
- MolDX: Breast Cancer Index (BCI) Gene Expression Test
- MolDX: EndoPredict Breast Cancer Gene Expression Test
- MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells
- Agenda [PDF]
|
Recording and Transcript |
All |
10/22/19 |
- MolDX: Molecular Microscope® Diagnostic System for the Heart
- MolDX: SelectMDx for Prostate Cancer
- MolDX: Signatera and Minimal Residual Disease Testing for Colorectal Cancer
- MolDX: Tests on allograft kidney biopsy tissue to assess for graft rejection
- MolDX: Oncotype AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC)
- MolDX: DecisionDX Melanoma
- MolDX: Razor 14-Gene Lung Cancer Assay
- MolDX: Repeat Germline Testing
- MolDX: AlloSure® Cell-Free DNA Testing
- MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Favorable Intermediate Risk Disease
- MolDX: Combinatorial Pharmacogenomics Limited Coverage
- MolDX - Pharmacogenomics Testing
- MolDX: Erythrocyte Molecular Antigen Typing
|
Recording and Transcript |